NCT01377922 2018-01-04A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Catalyst Pharmaceuticals, Inc.Phase 3 Completed38 enrolled 12 charts